SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 7.56% Passive Stake in Orthofix Medical Inc.
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd have disclosed a 7.56% beneficial ownership stake in Orthofix Medical Inc., holding 2,964,000 shares of common stock.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Orthofix Medical Inc.
- The Reporting Persons collectively beneficially own 2,964,000 shares of Orthofix Medical Inc. common stock.
- This ownership represents 7.56% of the company's outstanding common stock.
- The percentage is calculated based on 39,180,833 shares outstanding as of May 2, 2025, as reported in Orthofix Medical Inc.'s Form 10-Q filed on May 6, 2025.
- Armistice Capital, LLC, as the investment manager for Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of ownership, not a performance report or strategic announcement. The certification states the holding is for ordinary course of business and not for control.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by Armistice Capital, an investment firm, in Orthofix Medical Inc., a company operating in the medical device sector. Such filings are common for institutional investors accumulating stakes in publicly traded companies, reflecting their investment strategy within the healthcare industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
- Investors: Offers insight into institutional investment activity in Orthofix Medical Inc.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement. |
| 05/02/2025 | Date as of which 39,180,833 shares outstanding were reported by the Issuer. |
| 05/06/2025 | Date Orthofix Medical Inc. filed its Form 10-Q, reporting shares outstanding. |
| 05/15/2025 | Date of signing and filing of this Schedule 13G/A. |
Keywords
Orthofix Medical Inc., Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Medical Devices, Healthcare Investment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.